Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 3:15:5167-5182.
doi: 10.2147/IDR.S373183. eCollection 2022.

COVID-19 Vaccination Breakthrough Infections in a Real-World Setting: Using Community Reporters to Evaluate Vaccine Effectiveness

Matthew W Reynolds  1 , Yiqiong Xie  1 , Kendall B Knuth  1 , Christina D Mack  1 , Emma Brinkley  1 , Stephen Toovey  2 , Nancy A Dreyer  1
Affiliations

COVID-19 Vaccination Breakthrough Infections in a Real-World Setting: Using Community Reporters to Evaluate Vaccine Effectiveness

Matthew W Reynolds et al. Infect Drug Resist. .

Erratum in

Abstract

Purpose: Coronavirus disease 2019 (COVID-19) has highlighted the need for new methods of pharmacovigilance. Here, we use adult community volunteers to obtain systematic information on vaccine effectiveness and the nature and severity of breakthrough infections.

Methods: Between December 15, 2020 and September 16, 2021, 11,826 unpaid community-based volunteers reported the following information to an on-line registry: COVID-19 test results, vaccination (Pfizer, Moderna, or Johnson & Johnson) and COVID-19 symptoms. COVID-19 infections were described based on vaccination status at the time of infection: 1) fully vaccinated, 2) partially vaccinated (received first of two-dose vaccines or were <14 days post-final dose), or 3) unvaccinated.

Results: Among 8554 participants who received any COVID-19 vaccine, COVID-19 infections were reported by 74 (1.0%) of those who were fully vaccinated and 198 (2.3%) of those who were partially vaccinated at the time of infection. Among the 74 participants who reported a breakthrough infection after full vaccination, the median time from vaccination to reported positive test result was 104.5 days (interquartile range: 77-135 days), with no difference among vaccine manufacturers. One quarter (25.7%) of breakthrough infections in the fully vaccinated cases were asymptomatic and most (>97%) fully vaccinated participants reported no symptoms or only mild symptoms compared to 89.3% of the unvaccinated cases. Only 1.4% of fully vaccinated participants reported experiencing at least 3 moderate-to-severe symptoms compared to 7.8% in the unvaccinated.

Conclusion: Person-generated health data, also referred to as patient-reported outcomes, is a useful approach for quantifying breakthrough infections and their severity and for comparing vaccines.

Trial registration: Clinicaltrials.gov NCT04368065, EU PAS Register EUPAS36240.

Keywords: COVID-19; SARS-CoV-2; breakthrough infections; patient-reported outcomes; symptoms; vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Figure 1
Figure 1
COVID-19 breakthrough infection journey by manufacturer of COVID vaccine (A Janssen; B Pfizer-BioNTech or Moderna).
Figure 2
Figure 2
Flowchart of study sample and participant counts with COVID-19 infection.
Figure 3
Figure 3
Percentage of COVID-19 infected participants with symptoms by vaccination status.
Figure 4
Figure 4
Number of symptoms among COVID-19 infected participants by vaccination status.
Figure 5
Figure 5
Number of moderate or severe symptoms among COVID-19 infected participants by vaccination status.
Figure 6
Figure 6
Percentage of hospitalized participants among COVID-19 infected by vaccination status.
See this image and copyright information in PMC

References

    1. Baden LR, El Sahly HM, Essink B., et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020;384(5):403–416. doi:10.1056/NEJMoa2035389 - DOI - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–2201. doi:10.1056/NEJMoa2101544 - DOI - PMC - PubMed
    1. Choi A, Ibanez LI, Strohmeier S, Krammer F, Garcia-Sastre A, Schotsaert M. Non-sterilizing, infection-permissive vaccination with inactivated influenza virus vaccine reshapes subsequent virus infection-induced protective heterosubtypic immunity from cellular to humoral cross-reactive immune responses. Front Immunol. 2020;11:1166. doi:10.3389/fimmu.2020.01166 - DOI - PMC - PubMed
    1. U.S. Food and Drug Administration. Guideline for Postmarketing Reporting of Adverse Drug Experiences. Rockville, MD: US Food and Drug Administration; 1992.

Associated data